Vitae Pharmaceuticals (VTAE) Reports In-Line Q4 Loss of 40c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Vitae Pharmaceuticals (VTAE) Reports In-Line Q4 Loss of 40c/Share
March 31, 2015 7:02 AM EDT
FORT WASHINGTON, Pa., March 31, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the fourth quarter and full year ended December 31, 2014.
"We continue to make significant progress in advancing our RORt program with our lead proprietary candidate, VTP-43742 for the treatment of autoimmune disorders, towards initiation of a Phase 1 single ascending dose study," said Jeffrey Hatfield, President and Chief Executive Officer of Vitae. "In addition, we recently completed a successful follow-on offering, providing us with the capital to further the development of our... More
March 31, 2015 7:01 AM EDT
FORT WASHINGTON, Pa., March 31, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the fourth quarter and full year ended December 31, 2014.
"We continue to make significant progress in advancing our RORt program with our lead proprietary candidate, VTP-43742 for the treatment of autoimmune disorders, towards initiation of a Phase 1 single ascending dose study," said Jeffrey Hatfield, President and Chief Executive Officer of Vitae. "In addition, we recently completed a successful follow-on offering, providing us with the capital to further the development of our... More
